Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Mar 10.
doi: 10.1186/s13643-026-03153-6. Online ahead of print.

The use of GLP-1 receptor agonists and co-agonists in adults without diabetes: a systematic review and network meta-analysis protocol

Areesha Moiz  1 , Pauline Reynier  1 , Michael A Tsoukas  2   3 , Oriana Hy Yu  1   2   3   4 , Tricia M Peters  1   2   3   4 , Mark J Eisenberg  1   2   4   5 , Kristian B Filion  6   7   8
Affiliations
Free article

The use of GLP-1 receptor agonists and co-agonists in adults without diabetes: a systematic review and network meta-analysis protocol

Areesha Moiz et al. Syst Rev. .
Free article

Abstract

Background: Despite the increasing clinical use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), head-to-head evidence across these agents remains limited. This systematic review and network meta-analysis (NMA) will assess the comparative efficacy and safety of GLP-1 RAs and novel co-agonists for weight loss among adults without diabetes.

Methods: We will systematically search the PubMed, Ovid, and Cochrane CENTRAL databases to identify randomized controlled trials (RCTs) comparing a GLP-1 RA/co-agonist to placebo or another GLP-1 RA/co-agonist. We will restrict inclusion to RCTs in adults with overweight or obesity; those including participants with diabetes, specific comorbidities or diseases, or history of bariatric surgery will be excluded. The primary outcome will be weight loss, expressed as relative change from baseline, assessed at 6 months (± 4 weeks) and 1-1.5 years (± 4 weeks). Secondary outcomes will include absolute body weight change, total adverse events, gastrointestinal adverse events, serious adverse events, and death. Pairwise meta-analyses and frequentist NMAs will be conducted using a random-effects model. Treatment rankings for efficacy and safety outcomes will be generated using the surface under the cumulative ranking curve. The validity of the results and the assumptions underlying the analyses will be evaluated using a local and global approach. Study-level quality will be assessed using the Cochrane Risk of Bias (RoB) 2 tool and overall network quality will be assessed using the RoB-NMA tool.

Discussion: We aim to provide an up-to-date synthesis of RCTs assessing the weight loss effects of GLP-1 RAs and co-agonists among adults without diabetes to support future clinical decision-making, guideline development, and policy decisions.

Systematic review registration: PROSPERO CRD420251009368.

Keywords: GLP-1 receptor agonist; Network meta-analysis; Obesity; Randomized controlled trial; Weight loss.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: MAT has received speaker honoraria from Novo Nordisk, Eli Lilly, Boehringer-Ingelheim, and Sanofi. KBF has received speaker honoraria from Regeneron and Statlog, unrelated to the present work. All other authors declare that they have no competing interests.

References

    1. Phelps NH, Singleton RK, Zhou B, Heap RA, Mishra A, Bennett JE, et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–50.
    1. Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33(7):673–89.
    1. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation. 2006;113(6):898–918.
    1. Yurista SR, Eder RA, Feeley M, Kodur N, Tang WHW, Nguyen CT. A closer look at ACC/AHA and ESC guidelines for managing obesity and overweight in adults. JACC: Advances. 2023;2(7):100570.
    1. Butryn ML, Webb V, Wadden TA. Behavioral treatment of obesity. Psychiatr Clin North Am. 2011;34(4):841–59.

LinkOut - more resources